Stock Research: Novartis

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Novartis

SWX:NOVN CH0012005267
29
  • Value
    20
  • Growth
    39
  • Safety
    Safety
    39
  • Combined
    10
  • Sentiment
    79
  • 360° View
    360° View
    29
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Novartis AG is a pharmaceutical company that develops and markets branded and generic prescription drugs. It operates in the pharmaceutical industry, with focus on immunology, dermatology, cancer, and more. Novartis operates globally, with a strong presence in Switzerland. In the last fiscal year, the company had a market cap of $253,332 million, profits of $38,907 million, revenue of $51,722 million, and 75883 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 29 (better than 29% compared with alternatives), overall professional sentiment and financial characteristics for the stock Novartis are below the industry average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Novartis. The consolidated Sentiment Rank has a good rank of 79, which means that professional investors are more optimistic about the stock than for 79% of alternative investment opportunities. But all other ranks are below average. The consolidated Value Rank has a rank of 39, which means that the share price of Novartis is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 39, meaning that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth, and stock returns. This means that growth is lower than for 39% of competitors in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 20 which means that the company has a riskier financing structure than 80% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Dividends Europe
Diversity Europe
Moonshot Tech
SPI
SMI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 42 53 74
Growth
39 28 25 39
Safety
Safety
20 9 22 10
Sentiment
79 74 84 68
360° View
360° View
29 17 37 36
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
9 13 34 33
Opinions Change
72 82 87 49
Pro Holdings
n/a 81 70 92
Market Pulse
86 69 61 47
Sentiment
79 74 84 68
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
39 42 53 74
Growth
39 28 25 39
Safety Safety
20 9 22 10
Combined
10 1 8 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
57 60 59 75
Price vs. Earnings (P/E)
21 18 24 48
Price vs. Book (P/B)
14 17 26 55
Dividend Yield
76 85 90 90
Value
39 42 53 74
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
12 14 6 26
Profit Growth
62 39 48 43
Capital Growth
25 47 31 63
Stock Returns
63 64 62 52
Growth
39 28 25 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
24 25 40 19
Refinancing
7 13 9 1
Liquidity
62 59 55 54
Safety Safety
20 9 22 10

Similar Stocks

Discover high‑ranked alternatives to Novartis and broaden your portfolio horizons.

ALSO

SWX:ALSN
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

SoftwareONE Holding

SWX:SWON
Country: Switzerland
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.